I-SPY in the News
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
